Handok-Doctor Diary Collaborate for Digital Diabetes Management

Handok and digital healthcare startup Doctor Diary are collaborating for the digital transformation of chronic disease management.

Kim Young-jin, Chairman of Handok (left), and Song Je-yoon, CEO of Dr. Diary, are posing for a commemorative photo at the signing ceremony for 'Equity Investment and Strategic Partnership for Chronic Disease Management.'
[Photo by Handok]

Handok and Doctor Diary announced on the 6th that they signed an “Equity Investment and Strategic Partnership for Chronic Disease Management” contract on the 5th at Handok’s headquarters in Yeoksam-dong, Gangnam-gu, Seoul. The two companies plan to create public value in non-medical areas by leveraging their respective digital platforms, products, and experience and capabilities in the chronic disease business.

First, the two companies will cooperate on digital healthcare services for managing diabetes, a representative chronic disease. They aim to build a digital healthcare ecosystem that contributes to more proactive prevention and management of the increasing number of diabetes patients, activation of personalized health management services, and improvement of medical quality. To this end, they plan to establish health management services using digital technology and link them with primary medical institutions so that patients can receive personalized health management. In particular, based on digital technology and data, they will help medical staff manage patients and assist patients in improving their lifestyle habits by providing personalized plan development and monitoring of management status.

Doctor Diary provides a multi-solution combining IT technology, hardware, and content centered on the blood sugar management platform “Doctor Diary,” developed directly by type 2 diabetes patients. Last year, it obtained first-class certification for non-medical health management services focused on chronic disease management.

Handok, as a total diabetes solution company, offers various options across all areas of diabetes from diagnosis to treatment and management. It has launched products such as the sulfonylurea single agent “Amaryl,” combination drugs “Amaryl M” and “Amaryl MEX,” and the dipeptidyl peptidase (DPP)-4 inhibitor “Tenelia.” In addition, Handok started the industry’s first diabetes management education program in collaboration with academia and has continuously conducted the social contribution campaign “Dangdang Balgeoreum Campaign” since 2009 to raise awareness of the importance of blood sugar management and the risks of diabetic foot, a fatal complication.

Kim Young-jin, Chairman of Handok, said, “For chronic diseases like diabetes, management is as important as treatment, and integrating digital technology allows for more effective personalized health management. We will combine Handok’s long-standing experience and deep understanding in the diabetes field with Doctor Diary’s excellent digital capabilities to provide digital healthcare solutions that benefit both medical staff and patients.” Song Jeyoon, CEO of Doctor Diary, also said, “It is significant that we can collaborate in the non-medical area of chronic disease management, which is a national concern. We will build a close cooperative relationship based on trust.”

This content was produced with the assistance of AI translation services.